Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued on Tuesday. The brokerage set a “hold” rating on the stock.

EKSO has been the subject of a number of other reports. HC Wainwright dropped their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. Lake Street Capital dropped their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th.

Ekso Bionics Stock Performance

Shares of EKSO opened at $0.72 on Tuesday. The company’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.11. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The company has a market capitalization of $15.77 million, a price-to-earnings ratio of -1.10 and a beta of 1.47. Ekso Bionics has a 1 year low of $0.71 and a 1 year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. During the same period in the prior year, the business posted ($0.24) earnings per share. On average, sell-side analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC increased its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.